Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Diabeloop Obtains CE Marking for Its DBLG1tm


PARIS, November 12, 2018 /PRNewswire/ --

The disruptive innovation for autonomous management of T1D  

Diabeloop announced today it has received the CE marking for the DBLG1tm, its innovative technological solution to radically improve quality of life for T1D patients through better blood sugar management. This news represents an important step towards the commercial release of the product.  

Developed both for and with the patients, together with a team of engineers and medical researchers, the DBLG1tm? is at the heart of an hybrid closed-loop system integrating powerful algorithms into a secured terminal. Linked to a continuous blood glucose monitoring system and a insulin patch pump, it can predict glucose levels and command the insulin pump at an optimal rate. This self-learning and highly customizable system can reproduce the insulin-dispensing functions of a pancreas and adapt to the patient's physiology and lifestyle.

The Diabeloop device will lighten the heavy mental burden associated with diabetes and prevent both low blood sugar events (hypoglycemia), that are responsible for faintness and sometimes coma in the short term, and hyperglycemia, itself responsible for major complications in the long run. This represents a major breakthrough for the patients, their relatives and health professionals regarding this disease management.

"Weare proud to have passed the regulatory step of the CE marking. Our commercial deployment will be gradual in order to ensure quality of our product and our service towards the patients. We will also keep working for the reimbursement of our system as soon as possible,"? said Erik Huneker, co-CEO and founder of Diabeloop.

In Europe, CE marking is an essential stage in the DBLG1tm??System marketing process.

"Withthis certification, we're getting closer to the market launch and will move towards a new funding round to support our international scaling and our ambitious R&D roadmap. We hope to do all that by the second quarter of 2019,"? added Marc Julien, Diabeloop co-CEO and CFO.

About Diabeloop :  


These press releases may also interest you

at 00:30
Frost & Sullivan recently researched the data center colocation services industry and, based on its findings, recognizes STT GDC India with the 2023 Indian Company of the Year Award. STT GDC India is a pioneer data center solutions provider that...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

at 00:24
In the news release, Roborock Reports 2023 Full Year Financial Results, issued 28-Mar-2024 by Roborock over PR Newswire, we are advised by the company that in the first bullet point of "Growth across Product Categories", the USD amount should read...

28 mar 2024
The opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2024 was held in Boao, south China's Hainan Province on Thursday, with China's top legislator Zhao Leji stressing China's economic potential, appealing to international investors...

28 mar 2024
OKX Ventures, the investment arm of leading Web3 technology company OKX, has issued updates for March 29, 2024. OKX Ventures...

28 mar 2024
Curio Legacy Ventures (Curio), a frontrunner in nuclear technology innovation, proudly announces a strategic partnership with Navarro Research and Engineering, Inc. (Navarro). This collaboration signals a significant step forward in advancing nuclear...



News published on and distributed by: